Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 176

1.

Pathogen-induced proapoptotic phenotype and high CD95 (Fas) expression accompany a suboptimal CD8+ T-cell response: reversal by adenoviral vaccine.

Vasconcelos JR, Bruña-Romero O, Araújo AF, Dominguez MR, Ersching J, de Alencar BC, Machado AV, Gazzinelli RT, Bortoluci KR, Amarante-Mendes GP, Lopes MF, Rodrigues MM.

PLoS Pathog. 2012;8(5):e1002699. doi: 10.1371/journal.ppat.1002699. Epub 2012 May 17.

2.

Perforin and gamma interferon expression are required for CD4+ and CD8+ T-cell-dependent protective immunity against a human parasite, Trypanosoma cruzi, elicited by heterologous plasmid DNA prime-recombinant adenovirus 5 boost vaccination.

de Alencar BC, Persechini PM, Haolla FA, de Oliveira G, Silverio JC, Lannes-Vieira J, Machado AV, Gazzinelli RT, Bruna-Romero O, Rodrigues MM.

Infect Immun. 2009 Oct;77(10):4383-95. doi: 10.1128/IAI.01459-08. Epub 2009 Aug 3.

4.

Delivery of antigenic candidates by a DNA/MVA heterologous approach elicits effector CD8(+)T cell mediated immunity against Trypanosoma cruzi.

Gupta S, Garg NJ.

Vaccine. 2012 Nov 26;30(50):7179-86. doi: 10.1016/j.vaccine.2012.10.018. Epub 2012 Oct 15.

5.

Heterologous plasmid DNA prime-recombinant human adenovirus 5 boost vaccination generates a stable pool of protective long-lived CD8(+) T effector memory cells specific for a human parasite, Trypanosoma cruzi.

Rigato PO, de Alencar BC, de Vasconcelos JR, Dominguez MR, Araújo AF, Machado AV, Gazzinelli RT, Bruna-Romero O, Rodrigues MM.

Infect Immun. 2011 May;79(5):2120-30. doi: 10.1128/IAI.01190-10. Epub 2011 Feb 28.

6.

Efficient protective immunity against Trypanosoma cruzi infection after nasal vaccination with recombinant Sendai virus vector expressing amastigote surface protein-2.

Duan X, Yonemitsu Y, Chou B, Yoshida K, Tanaka S, Hasegawa M, Tetsutani K, Ishida H, Himeno K, Hisaeda H.

Vaccine. 2009 Oct 19;27(44):6154-9. doi: 10.1016/j.vaccine.2009.08.026. Epub 2009 Aug 25.

PMID:
19712768
7.

Vaccination using recombinants influenza and adenoviruses encoding amastigote surface protein-2 are highly effective on protection against Trypanosoma cruzi infection.

Barbosa RP, Filho BG, Dos Santos LI, Junior PA, Marques PE, Pereira RV, Cara DC, Bruña-Romero O, Rodrigues MM, Gazzinelli RT, Machado AV.

PLoS One. 2013 Apr 24;8(4):e61795. doi: 10.1371/journal.pone.0061795. Print 2013.

8.

Prophylactic efficacy of TcVac2 against Trypanosoma cruzi in mice.

Gupta S, Garg NJ.

PLoS Negl Trop Dis. 2010 Aug 10;4(8):e797. doi: 10.1371/journal.pntd.0000797.

9.

Immune responses against a single CD8+-T-cell epitope induced by virus vector vaccination can successfully control Trypanosoma cruzi infection.

Miyahira Y, Takashima Y, Kobayashi S, Matsumoto Y, Takeuchi T, Ohyanagi-Hara M, Yoshida A, Ohwada A, Akiba H, Yagita H, Okumura K, Ogawa H.

Infect Immun. 2005 Nov;73(11):7356-65.

11.

Infection with Trypanosoma cruzi restricts the repertoire of parasite-specific CD8+ T cells leading to immunodominance.

Tzelepis F, de Alencar BC, Penido ML, Claser C, Machado AV, Bruna-Romero O, Gazzinelli RT, Rodrigues MM.

J Immunol. 2008 Feb 1;180(3):1737-48.

13.
14.

Coadministration of an interleukin-12 gene and a Trypanosoma cruzi gene improves vaccine efficacy.

Katae M, Miyahira Y, Takeda K, Matsuda H, Yagita H, Okumura K, Takeuchi T, Kamiyama T, Ohwada A, Fukuchi Y, Aoki T.

Infect Immun. 2002 Sep;70(9):4833-40.

15.

Efficacy of a trans-sialidase-ISCOMATRIX subunit vaccine candidate to protect against experimental Chagas disease.

Bontempi IA, Vicco MH, Cabrera G, Villar SR, González FB, Roggero EA, Ameloot P, Callewaert N, Pérez AR, Marcipar IS.

Vaccine. 2015 Mar 3;33(10):1274-83. doi: 10.1016/j.vaccine.2015.01.044. Epub 2015 Jan 25.

PMID:
25625671
16.

Effect of a combination DNA vaccine for the prevention and therapy of Trypanosoma cruzi infection in mice: role of CD4+ and CD8+ T cells.

Limon-Flores AY, Cervera-Cetina R, Tzec-Arjona JL, Ek-Macias L, Sánchez-Burgos G, Ramirez-Sierra MJ, Cruz-Chan JV, VanWynsberghe NR, Dumonteil E.

Vaccine. 2010 Oct 28;28(46):7414-9. doi: 10.1016/j.vaccine.2010.08.104. Epub 2010 Sep 16.

PMID:
20850536
17.

Challenge of chronically infected mice with homologous trypanosoma cruzi parasites enhances the immune response but does not modify cardiopathy: implications for the design of a therapeutic vaccine.

Rosas-Jorquera CE, Sardinha LR, Pretel FD, Bombeiro AL, D'Império Lima MR, Alvarez JM.

Clin Vaccine Immunol. 2013 Feb;20(2):248-54. doi: 10.1128/CVI.00032-12. Epub 2012 Dec 19.

18.

Comparison of antibody and protective immune responses against Trypanosoma cruzi infection elicited by immunization with a parasite antigen delivered as naked DNA or recombinant protein.

Pereira-Chioccola VL, Costa F, Ribeirão M, Soares IS, Arena F, Schenkman S, Rodrigues MM.

Parasite Immunol. 1999 Feb;21(2):103-10.

19.

Swimming against the current: genetic vaccination against Trypanosoma cruzi infection in mice.

Rodrigues MM, de Alencar BC, Claser C, Tzelepis F, Silveira EL, Haolla FA, Dominguez MR, Vasconcelos JR.

Mem Inst Oswaldo Cruz. 2009 Jul;104 Suppl 1:281-7.

20.

Vaccination with DNA encoding the immunodominant LACK parasite antigen confers protective immunity to mice infected with Leishmania major.

Gurunathan S, Sacks DL, Brown DR, Reiner SL, Charest H, Glaichenhaus N, Seder RA.

J Exp Med. 1997 Oct 6;186(7):1137-47.

Items per page

Supplemental Content

Write to the Help Desk